WACO, Texas -- Baylor University researchers, working with the United States Environmental Protection Agency, have detected low-level residues of several human medications and personal care products in fish collected from effluent-dominated rivers, including the residue of one pharmaceutical in wild fish that has not been previously reported.
These findings are part of the first EPA pilot study designed to look for the occurrence of pharmaceuticals and personal care products (PPCPs) in fish from our nation’s waterways.
“While this study found the residue of several pharmaceuticals and personal care products in fish tissue, it also demonstrated for the first time that fish from several different locations across the country are exposed to multiple PPCPs in effluent-dominated waterways,” said Dr. Bryan Brooks, associate professor of environmental sciences at Baylor and an aquatic toxicology expert on PPCPs who is a Baylor co-lead investigator on the study.
The study’s methodology is presented today at the spring 2009 National Meeting of the American Chemical Society in Salt Lake City by Dr. Kevin Chambliss, a Baylor co-lead investigator with Brooks. The study’s results also are scheduled to be published on-line in a special edition of Environmental Toxicology and Chemistry. The special issue will be dedicated to PPCPs found in the environment.
The study was funded by a contract from the EPA with Tetra Tech, a leading provider of consulting, engineering and technical services. The Baylor University team, led by Chambliss and Brooks, was contracted by Tetra Tech to use their innovative PPCP detection methodologies in fish tissue to conduct the pilot study.
Many aquatic systems throughout the United States routinely receive effluent discharges from wastewater treatment plants. Sometimes, the flow of streams and rivers can become dominated by these effluents. Although there are federal standards for treated wastewater, no guidelines or federal testing standards exist for pharmaceuticals or most personal care products in wastewater because their effects in surface waters are not well understood. EPA undertook this pilot study as a part of an overall strategy to better understand the occurrence of PPCPs in surface waters, sediment and fish tissue.
The study involved collection of fish from five effluent-dominated rivers in various parts of the country. The sampling locations included discharge areas of wastewater treatment plants in Chicago, Dallas, Orlando, Fla., Phoenix, and West Chester, Pa., near Philadelphia. The Gila River Wilderness Area in New Mexico provided a suitable reference site for the study, because it is isolated from human sources of pollution.
The Baylor researchers tested fish fillets and liver tissue for 24 different human medications. The researchers also tested fish fillets for 12 chemicals found in personal care products. The study results revealed that:
“We found the highest concentrations and frequencies of compounds in the fish livers but considering that the liver is the primary site of metabolism for xenobiotics in fish, as in humans, this result is logical.” said Chambliss, associate professor of chemistry and biochemistry at Baylor.
While the impact these compounds have on fish is not yet fully understood, it is documented in the scientific literature that antidepressant accumulation in fish may cause certain behavioral changes, which impact aggression, mating and other behaviors necessary for fish survival.
Based on the pilot study findings, EPA is expanding its investigation of PPCPs in fish under its National Rivers and Streams Assessment. Fish collection began in 2008 and is continuing in 2009.
Views expressed in this article do not necessarily reflect those of UnderwaterTimes.com, its staff or its advertisers.